News – Page 667 – Endpoints News

On a mission to treat patients not covered by Luxturna, Horama refuels with a Series B expansion and a new name

4 years ago

Albireo caps a big week with back-to-back approvals in the US/EU for the first drug to treat a severe liver disease

4 years ago

A Novartis castoff with a troubled past headlines Chinese biotech's Hong Kong IPO quest

4 years ago

Relmada to explore psychedelic avenue in pursuit of depression treatment; Italian manufacturer joins NYSE

4 years ago

Delta variant's rapid rise — now spurring 83% of new cases — sends stocks spiraling in what CDC director calls a ...

4 years ago

Can a next-gen take on a deadly weight loss pill conquer cardiometabolic diseases? A Medicxi-backed startup thinks so

4 years ago

PacBio engineers $800M buyout of sequencing rival Omniome as analysts fret over FTC action

4 years ago

FDA rejects professor’s petition seeking to pull ‘dangerous’ Otsuka kidney disease drug

4 years ago

Industry groups warn of drug shortages linked to widespread carcinogen testing as FDA doubles down on its approach

4 years ago

A top Morgan Stanley sell-side analyst makes the jump from outside player to biotech C-suite insider

4 years ago

GHO Capital Partners doubles its last raise, closing on a massive $2B-plus to advance European healthcare

4 years ago

Terms of mega opioid settlement set to be disclosed this week — report

4 years ago

The next SPAC is here, coming from a pharma e-commerce CEO, as a Florida biotech prices at the low end

4 years ago

A pair of young biotech execs snag a mega-round for their late-stage ALS drug as the FDA signals a more flexible ...

4 years ago

Sean Parker-backed cell therapy startup ArsenalBio plucks Merck VP as new CSO

4 years ago

Gilead still hasn't made up its mind about Arcus' drugs, but there's a top exec at the biotech it definitely wants

4 years ago

On a mission to support 'underserved' European startups, Panakès Partners dips into the biotech sector with its ...

4 years ago

Chinese antibody player chases Hong Kong IPO with lead Rituxan challenger ready for late-stage test

4 years ago

Ardelyx craters after FDA stuns analysts and rejects their kidney disease pitch

4 years ago

Soros, Gates back medtech's move into a 'social enterprise'; Aging anti-rejection drug earns fresh approval

4 years ago

Months after Amgen's landmark KRAS approval, Chris Varma bags a crossover round for next-gen candidate

4 years ago

PureTech-backed Gelesis wins biotech's latest SPAC deal, planning to bring weight loss product to up to 150M ...

4 years ago

Merck KGaA fortifies its ‘site of the future’ with $319M research, staff training centers

4 years ago

FDA’s domestic biopharma inspections return to normal as agency faces backlog of 8,000+

4 years ago

First page Previous page 664 665 666667668 669 670 Next page Last page